Hydroxyurea: all 134 studies that test it
Page 1 of 2. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.
- Addition of Hydroxyurea to Fludarabine, Cytarabine, Idarubicin and Venetoclax Salvage Therapy for Adults With Relapsed or Refractory Acute Myeloid LeukemiaNot yet recruitingNCT07766850Phase 1/2
- Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) StudyRecruitingNCT07708714Phase 1/2
- Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta ThalassemiaRecruitingNCT07673302Not applicable
- Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell DiseaseRecruitingNCT07616154Phase 2
- A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)RecruitingNCT07190833Phase 1
- Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT06871410Phase 1
- Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell DiseaseRecruitingNCT06578507Phase 2
- Stroke Prevention in Nigeria 2 TrialRecruitingNCT06526117Phase 4
- Primary Prevention of Stroke in Children With Sickle Cell Anaemia in Nigeria in the CommunityRecruitingNCT05434000Not applicable
- Promoting Utilization and Safety of Hydroxyurea Using Precision in AfricaRecruitingNCT05285917Phase 3
- T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other AnemiasRecruitingNCT03653338Phase 1/2
- Lung and Bone Marrow Transplantation for Lung and Bone Marrow FailureRecruitingNCT03500731Phase 1/2
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTRecruitingNCT01962415Phase 2
- Hydroxyurea and EPO in Sickle Cell DiseaseCompletedNCT05451940Phase 1/2Results posted
- A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Hydroxycarbamide in Healthy VolunteersCompletedNCT05025072Phase 1Results posted
- Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring SideroblastsTerminatedNCT05005182Phase 2Results posted
- Hydroxyurea Therapy: Optimizing Access in Pediatric Populations EverywhereTerminatedNCT03825341Phase 2Results posted
- SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)CompletedNCT03806452Phase 2Results posted
- Pharmacokinetics of Oral Hydroxyurea SolutionCompletedNCT03763656Phase 1/2Results posted
- Management of Severe Acute Malnutrition in SCD, in Northern NigeriaCompletedNCT03634488Phase 2Results posted
- Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)CompletedNCT03263559Phase 2Results posted
- Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell DiseaseActive, not recruitingNCT03077542Phase 1/2Results posted
- Hydroxyurea Management in Kids: Intensive Versus Stable Dosage StrategiesCompletedNCT03020615Phase 2Results posted
- Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone MarrowCompletedNCT02757885Phase 2Results posted
- Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)TerminatedNCT02640573Phase 2Results posted
- Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)CompletedNCT02522104Phase 4Results posted
- Treatment of Hemoglobin SC Disease With HydroxyureaTerminatedNCT02336373Phase 2Results posted
- Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell DiseaseCompletedNCT02225132Phase 1/2Results posted
- Novel Use Of Hydroxyurea in an African Region With MalariaCompletedNCT01976416Phase 3Results posted
- Realizing Effectiveness Across Continents With Hydroxyurea (REACH)Active, not recruitingNCT01966731Phase 1/2Results posted
- Chemotherapy for Relapsed Epstein Barr Virus Associated LymphomaTerminatedNCT01964755Phase 2Results posted
- Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE)TerminatedNCT01531387Phase 3Results posted
- Transcranial Doppler (TCD) With Transfusions Changing to HydroxyureaTerminatedNCT01425307Phase 3Results posted
- Hydroxyurea to Prevent Brain Injury in Sickle Cell DiseaseCompletedNCT01389024Phase 2Results posted
- Combination of Hydroxyurea and Verapamil for Refractory MeningiomasCompletedNCT00706810Phase 2Results posted
- Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)CompletedNCT00615927Phase 2Results posted
- A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy PatientsCompletedNCT00568802Phase 1/2Results posted
- A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy PatientsCompletedNCT00568698Phase 1/2Results posted
- Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell DiseaseTerminatedNCT00532883Phase 2Results posted
- Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck CancerCompletedNCT00468169Phase 2Results posted
- Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck CancerCompletedNCT00462735Phase 2Results posted
- Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive MeningiomaCompletedNCT00354913Phase 2Results posted
- Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary HypertensionTerminatedNCT00350844Phase 1/2Results posted
- Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)TerminatedNCT00290771Phase 2Results posted
- Stroke With Transfusions Changing to HydroxyureaTerminatedNCT00122980Phase 3Results posted
- Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell AnemiaCompletedNCT00006400Phase 3Results posted
- S9811 Hydroxyurea in Treating Patients With Unresectable Benign MeningiomaCompletedNCT00003590Phase 2Results posted
- Long Term Beta Thalassemia Treatment: Findings From The Extension PeriodActive, not recruitingNCT06490601Phase 2
- Efficacy of Combination of Hdroxyurea and Thalidomide Over Hydroxyurea or Thalidomide in the Treatment of Transfusion Dependent Thalassemia in ChildrenCompletedNCT06299670Phase 4
- Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study.CompletedNCT06239389Phase 2
- Realizing Effectiveness Across Continents With HydroxyureaActive, not recruitingNCT06171217Phase 2
- Thalidomide and Hydroxyurea Combination in β-Thalassemia PatientsCompletedNCT06153784Phase 2/3
- Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM PredictorsTerminatedNCT05853458Phase 4
- Hydroxyurea Treatment for Adult Sickle Cell Anemia Patients in KinshasaCompletedNCT05681598Not applicable
- Alternative Dosing And Prevention of Transfusions (ADAPT)Active, not recruitingNCT05662098Early Phase 1
- Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.CompletedNCT05470270Phase 2
- Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-ThalassemiaActive, not recruitingNCT05357482Phase 1/2
- Clinical Experience of Thalidomide in Thalassemic PatientsCompletedNCT05132270Phase 2/3
- Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell AnemiaCompletedNCT05081349Phase 4
- Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II )CompletedNCT04750707Phase 3
- Reduced Intensity Transplantation for Severe Sickle Cell DiseaseActive, not recruitingNCT04362293Phase 2
- Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major ThalassemiaCompletedNCT04292314Phase 2/3
- Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)Active, not recruitingNCT03948867Phase 2
- Hydroxyurea Optimization Through Precision StudyCompletedNCT03789591Phase 3
- Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent ThalassemiaCompletedNCT03651102Phase 2/3
- Hydroxyurea and TransfusionCompletedNCT03644953Phase 2
- Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML PatientsStatus unknownNCT03515018Phase 3
- Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)Status unknownNCT03463733Phase 1
- The Efficacy and Safety of HYDROXYUREA in Management of Beta Thalassemia Patients in Karachi PakistanStatus unknownNCT03183375Phase 2
- Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic AreasCompletedNCT03128515Phase 3
- Hydroxyurea in the Emergency Room to Lessen Pain in Sickle Cell CrisisStatus unknownNCT03062501Phase 2
- Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment.Status unknownNCT02957760Phase 2
- SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell AnemiaCompletedNCT02769845Not applicable
- Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan AfricaCompletedNCT02675790Phase 3
- Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa IICompletedNCT02560935Phase 3
- EXTEND EXpanding Treatment for Existing Neurological DiseaseCompletedNCT02556099Phase 2
- Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)CompletedNCT02480608Phase 1/2
- Therapeutic Response Evaluation and Adherence Trial (TREAT)Active, not recruitingNCT02286154Not applicable
- Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMMLCompletedNCT02214407Phase 3
- Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea TreatmentCompletedNCT02149537Phase 4
- Risk-based Therapy for Sickle Cell Anemia: A Feasibility StudyWithdrawnNCT02090296Phase 2
- Novel Dose Escalation to Predict Treatment With HydroxyureaCompletedNCT02042222Early Phase 1
- Hydroxyurea in Pulmonary Arterial HypertensionWithdrawnNCT01950585Early Phase 1
- Sickle Cell Disease - Stroke Prevention in Nigeria TrialCompletedNCT01801423Not applicable
- Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)TerminatedNCT01645124Phase 3
- Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin.Status unknownNCT01624038Phase 2/3
- Future of Spermatogenesis in Men With Sickle Cell Disease Medically TreatedCompletedNCT01609192Phase 4
- A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid TumorsWithdrawnNCT01521299Phase 1
- Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell AnemiaCompletedNCT01506544Phase 1
- A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid NeoplasmsCompletedNCT01387763Phase 3
- Hydroxyurea in Primary Progressive Multiple SclerosisTerminatedNCT01103583Phase 2/3
- Effect of Hydroxyurea as Treatment for Primary Desmoid TumorsWithdrawnNCT00978146Phase 2
- Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia IntermediaCompletedNCT00809042Phase 2
- Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant GliomaCompletedNCT00613054Phase 1
- Hydroxyurea in Young Children With Sickle Cell AnemiaCompletedNCT00519701Not applicable
- A Trial of Hydroxyurea in Spinal Muscular AtrophyCompletedNCT00485511Phase 2/3
- Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow VelocityCompletedNCT00402480Phase 2
- Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant GliomaCompletedNCT00387933Phase 1
- Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia MajorCompletedNCT00336362Not applicable
- Hydroxyurea and Erythropoietin to Treat Sickle Cell AnemiaCompletedNCT00270478Phase 1